Jed A. Latkin
CEO, President & DirectorMr. Jed A. Latkin has been the Chief Executive Officer of Windtree Therapeutics, Inc. since December 01, 2024 and is its President since December 01, 2024 and was its Independent Director since August 13, 2024. He serves as Chief Operating Officer & Head of Finance Department of ProPhase Labs, Inc. since January 2023. In his capacity as Chief Operating Officer, he also serves as ProPhase Lab's principal financial officer and principal accounting officer. He was Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since October 1, 2018 until October 24, 2021. He had been Chief Financial Officer and Chief Operating Officer of Navidea Biopharmaceuticals, Inc. since May 04, 2017 until October 24, 2021. He served as Treasurer and Secretary at Navidea Biopharmaceuticals, Inc. since April 21, 2016. Mr. Latkin has more than twenty eight years of experience in the financial industry supporting many investments in major markets, including biotechnology and pharmaceuticals. Mr. Latkin previously served on the Board of Directors CORAR from October 2018 until October 2021. He also served as Interim Chief Operating Officer of Navidea Biopharmaceuticals, Inc. from April 2016 to April 2017. He was Interim Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since August 14, 2018 until October 1, 2018. He was Director of Navidea Biopharmaceuticals, Inc. since August 14, 2018 until October 24, 2021. Mr. Latkin served as a Turnaround Specialist at Nagel Avenue Capital, LLC, or Nagel Avenue Capital, an investment firm, from November 2021 to January 2023, where he provided contracted services for numerous companies and asset management firms and was responsible for a large diversified portfolio of asset-based investments in varying industries, including product manufacturing, agriculture, energy and healthcare. He has been responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy and healthcare. He most recently was employed by Nagel Avenue Capital, LLC since 2010 and in that capacity he provided contracted services as a Portfolio Manager, Asset Based Lending for Platinum Partners Value Arbitrage Fund L.P. He has been responsible for a large diversified portfolio of asset based investments in varying industries, including product manufacturing, agriculture, energy and healthcare. In connection with this role, he served as Chief Executive Officer of End of Life Petroleum Holdings, LLC and Black Elk Energy, LLC, Chief Financial Officer of Viper Powersports, Inc. and West Ventures, LLC and Portfolio Manager of Precious Capital, LLC. He served as Principal Executive Officer of Navidea Biopharmaceuticals, Inc. from May 17, 2016 to September 22, 2016. Prior to his position at Nagel Avenue Capital, LLC, he was a Senior Research Analyst, Global Markets for ING Investment Management and held various finance roles at Troika Dialog, Morgan Stanley, Citigroup Securities, Fleet Boston Robertson Stephens and Citicorp Securities. He served as Portfolio Manager of Asset Based Lending of Platinum Partners Value Arbitrage Fund L.P. since 2010 and was responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy, healthcare and consumer discretionary. He has experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals by providing executive direction and preserving operational control during transitional periods. He served on the boards of directors of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels. He served as a Director of Viper Powersports Inc. from August 23, 2012 to March 6, 2013. He earned a B.A. in Political Science and History from Rutgers University and a M.B.A. in Finance from Columbia Business School.
公司职务
- 公司名称Windtree Therapeutics, Inc.股票代码WINT职务CEO, President & Director共事同僚
